KYMR: Kymera Therapeutics, Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 6 sales totaling $3.41M in the last 180 days.
Insider sales
| Trade date | Insider | Role | Value | 10b5-1 plan |
|---|---|---|---|---|
| 2026-10-01 | Mainolfi Nello | CEO | $393K | yes |
| 2026-10-01 | Mainolfi Nello | CEO | $619K | yes |
| 2026-10-01 | Mainolfi Nello | CEO | $552K | yes |
| 2026-10-01 | Mainolfi Nello | CEO | $870K | yes |
| 2026-10-01 | Mainolfi Nello | CEO | $950K | yes |
| 2026-10-01 | Mainolfi Nello | CEO | $30K | yes |
Activist and 5% holders
| Filed | What | Holder | Stake | Change | Filing |
|---|---|---|---|---|---|
| 2026-09-08 | 13G stake raised | T. Rowe Price Associates, Inc. | 10.70% | +2.10 pts | SEC |
| 2026-08-14 | 13G amendment | T. Rowe Price Associates, Inc. | 8.60% | SEC | |
| 2026-08-13 | Fell below 5% | Atlas Venture Fund X, L.P. | 2.90% | SEC |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.